张瑶,田祥,张旗,甄利波,耿巍,刘倩梅,杨颖,宋达

• 1:保定市第一中心医院心内科
• 2:承德医学院

摘要(Abstract)：

目的探讨冠状动脉增强CT检查后1周内再次行冠状动脉造影(CAG)或经皮冠状动脉介入治疗(PCI)对患者肾功能的影响。方法选择就诊于保定市第一中心医院已行冠状动脉增强CT将进一步行CAG或PCI的患者258例,随机分为试验组132例和对照组126例,试验组为行冠状动脉增强CT检查后1周内再次行CAG或PCI,对照组的时间间隔为1~2周。监测两组患者术前和术后1、2、3 d血肌酸酐、胱抑素C水平,计算估算的肾小球滤过率(e GFR),并记录对比剂肾病(CIN)的发生率。结果两组患者的一般资料比较,差异均无统计学意义(均P>0.05)。两组患者间术前和术后1、2、3 d各时间点的血肌酸酐、胱抑素C、e GFR水平分别比较,差异均无统计学意义(均P>0.05)。试验组发生CIN 7例(5.3%),对照组发生CIN 6例(4.8%),两组比较,差异无统计学意义(P=0.843)。结论对于e GFR≥60 ml/(min·1.73 m2)的患者静脉应用对比剂行冠状动脉增强CT检查后1周内再次行CAG或PCI是安全可行的。

关键词(KeyWords)： 对比剂肾病;冠状动脉造影;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张瑶,田祥,张旗,甄利波,耿巍,刘倩梅,杨颖,宋达

参考文献(References)：

• [1]Seeliger E,Sendeski M,Rihal CS,et al.Contrast-induced kidney injury:mechanisms,risk factors,and prevention.Eur Heart J,2012,33(16):2007-2015.
• [2]Ribichini F,Gambaro G,Graziani MS,et al.Comparison of serum creatinine and cystatin C for early diagnosis of contrastinduced nephropathy after coronary angiography and interventions.Clin Chem,2012,58(2):458-464.
• [3]Stacul F,van der Molen AJ,Reimer P,et al.Contrast induced nephropathy:updated ESUR Contrast Media Safety Committee guidelines.Eur Radiol,2011,21(12):2527-2541.
• [4]Ebru AE,Kilic A,Korkmaz FS,et al.Is cystatin-C superior to creatinine in the early diagnosis of contrast-induced nephropathy:a potential new biomarker for an old complication.J Postgrad Med,2014,60(2):135-140.
• [5]Mehran R,Aymong ED,Nikolsky E,et al.A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention:development and initial validation.J Am Coll Cardiol,2004,44(7):1393-1399.
• [6]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.含碘对比剂在心血管疾病中临床应用的专家共识(2012).中华心血管病杂志,2013,41(2):94-98.
• [7]Neyra JA,Shah S,Mooney R,et al.Contrast-induced acute kidney injury following coronary angiography:a cohort study of hospitalized patients with or without chronic kidney disease.Nephrol Dial Transplant,2013,28(6):1463-1471.
• [8]Nash K,Hafeez A,Hou S.Hospital-acquired renal insufficiency.Am J Kidney Dis,2002,39(5):930-936.
• [9]Bucher AM,De Cecco CN,Schoepf UJ,et al.Is contrast medium osmolality a causal factor for contrast-induced nephropathy.Biomed Res Int,2014,2014:931413.
• [10]Geng W,Fu XH,Gu XS,et al.Preventive effects of anisodamine against contrast-induced nephropathy in type 2diabetics with renal insufficiency undergoing coronary angiography or angioplasty.Chin Med J(Engl),2012,125(19):3368-3372.
• [11]陈韵岱,陈纪言,傅国胜,等.碘对比剂血管造影应用相关不良反应中国专家共识.中国介入心脏病学杂志,2014,22(6):341-348.
• [12]Khwaja A.KDIGO clinical practice guidelines for acute kidney injury.Nephron Clin Pract,2012,120(4):c179-184.
• [13]Kim GS,Ko YG,Shin DH,et al.Elevated serum cystatin C level is an independent predictor of contrast-induced nephropathy and adverse outcomes in patients with peripheral artery disease undergoing endovascular therapy.J Vasc Surg,2015,61(5):1223-1230.
• [14]Briguori C,Visconti G,Rivera NV,et al.Cystatin C and contrast-induced acute kidney injury.Circulation,2010,121(19):2117-2122.
• [15]Andreucci M,Faga T,Pisani A,et al.Prevention of contrastinduced nephropathy through a knowledge of its pathogenesis and risk factors.Scientific World Journal,2014,2014:823169.
• [16]Katzberg RW,Lamba R.Contrast-induced nephropathy after intravenous administration:fact or fiction.Radiol Clin North Am,2009,47(5):789-800.
• [17]Kim SM,Cha RH,Lee JP,et al.Incidence and outcomes of contrast-induced nephropathy after computed tomography in patients with CKD:a quality improvement report.Am J Kidney Dis,2010,55(6):1018-1025.
• [18]陈侃,钱菊英,葛雷,等.冠状动脉介入诊疗术对肾功能影响的532例分析.中国介入心脏病学杂志,2009,17(3):153-156.
• [19]Calvin AD,Misra S,Pflueger A.Contrast-induced acute kidney injury and diabetic nephropathy.Nat Rev Nephrol,2010,6(11):679-688.
• [20]Palli E,Makris D,Papanikolaou J,et al.Contrast-induced nephropathy in aged critically ill patients.Oxid Med Cell Longev,2014,2014:756469.
• [21]Kane GC,Doyle BJ,Lerman A,et al.Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography.J Am Coll Cardiol,2008,51(1):89-90.
• [22]中华医学会放射学分会对比剂安全使用工作组.碘对比剂使用指南(第2版).中华放射学杂志,2013,47(10):869-872.